News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Oncolytics Biotech Inc. Announces Approval of US 40-F Registration (CCN Disclosure)..., and when activated, may account for a large proportion of all human tumors.......Oncolytics researchers demonstrated that the reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumors successfully in a number of animal models....- Jan 23 6:04 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/ccn/010123/b.html

Posted on: 01/23/2001

"Yahoo - Oncolytics Biotech Inc. Announces Approval of US 40-F Registration"
Yahoo! Finance Finance Home - Yahoo! - Help
Canadian Corp News

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ONC.TO
11.70
+0.00
delayed 20 mins - disclaimer
Tuesday January 23, 6:04 am Eastern Time

Press Release

Oncolytics Biotech Inc. Announces Approval of US 40-F Registration

CALGARY, ALBERTA--Oncolytics Biotech Inc. (TSE: ONC - news) reported today the Company filed a registration statement on Form 40-F with Securities and Exchange Commission to register the Common Shares of the Company under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company's Form 40F registration statement was declared effective on January 22, 2001, and the Company is now a reporting issuer under the Exchange Act. An outline of this registration statement can be accessed through the company's website (www.oncolyticsbiotech.com).

The Company has also recently received approval from the Quebec Securities Commission to be deemed a reporting issuer in the Province of Quebec.

The company has also received confirmation that its shares can be traded on the Deutsche Borse AG electronic trading system pursuant to Article 4 of the Rules for the Regulated Unofficial Market and Article 40 of the Rules and Regulations for the Frankfurt Stock Exchange.

Oncolytics is a Calgary-based biotechnology company focused on the development of the reovirus known as REOLYSIN® as a potential cancer therapeutic. This reovirus infects and kills cancer cells with an activated Ras pathway. Ras is an important component of a pathway controlling normal growth and differentiation of a cell, and when activated, may account for a large proportion of all human tumors. Researchers believe that targeting this pathway could have broad potential in the treatment of many cancers. Oncolytics researchers demonstrated that the reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumors successfully in a number of animal models. Oncolytics initiated its Phase I clinical trial on REOLYSIN® in June 2000 and in November 2000, the company entered into a worldwide licensing agreement with Pfizer Inc. for the development and marketing of the reovirus for animal use.


Contact:
Oncolytics Biotech Inc.
Doug Ball
Chief Financial Officer
(403) 670-7380
(403) 283-0858
Email: dougballonc@aol.com
Website: www.oncolyticsbiotech.com
or
Opsis Financial
Mr. David Wolk
Investor Relations Advisor
(416) 368-8998
(416) 368-8669
Email: dwolk@opsis.ca

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Oncolytics Biotech Inc (Toronto:ONC.TO - news)
Related News Categories: medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service

Copyright 2001 Canadian Corp News. CCN Disclosure All rights reserved. All news releases provided by CCN Disclosure are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740